Our product range includes a wide range of Osteoporosis such as Zoldonat Injection and Zoldria Injection.
Zoldonat inj. contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-hydroxy-2imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate.
Zoldonat is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density or prevalent vertebral fracture, Zoldonat reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Zoldonat reduces the incidence of new clinical fractures.
Zoldria (zoledronic acid) Injection is indicated for the treatment of hypercalcemia of malignancy.
Multiple Myeloma and Bone Metastases of Solid Tumors - Zoldria is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
Zoldria is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months.